Use of digoxin and risk of death or readmission for heart failure and sinus rhythm: A nationwide propensity score matched study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Standard

Use of digoxin and risk of death or readmission for heart failure and sinus rhythm : A nationwide propensity score matched study. / Madelaire, Christian; Schou, Morten; Nelveg-Kristensen, Karl Emil; Schmiegelow, Michelle; Torp-Pedersen, Christian; Gustafsson, Finn; Køber, Lars; Gislason, Gunnar.

I: International Journal of Cardiology, Bind 221, 15.10.2016, s. 944-50.

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Harvard

Madelaire, C, Schou, M, Nelveg-Kristensen, KE, Schmiegelow, M, Torp-Pedersen, C, Gustafsson, F, Køber, L & Gislason, G 2016, 'Use of digoxin and risk of death or readmission for heart failure and sinus rhythm: A nationwide propensity score matched study', International Journal of Cardiology, bind 221, s. 944-50. https://doi.org/10.1016/j.ijcard.2016.07.111

APA

Madelaire, C., Schou, M., Nelveg-Kristensen, K. E., Schmiegelow, M., Torp-Pedersen, C., Gustafsson, F., Køber, L., & Gislason, G. (2016). Use of digoxin and risk of death or readmission for heart failure and sinus rhythm: A nationwide propensity score matched study. International Journal of Cardiology, 221, 944-50. https://doi.org/10.1016/j.ijcard.2016.07.111

Vancouver

Madelaire C, Schou M, Nelveg-Kristensen KE, Schmiegelow M, Torp-Pedersen C, Gustafsson F o.a. Use of digoxin and risk of death or readmission for heart failure and sinus rhythm: A nationwide propensity score matched study. International Journal of Cardiology. 2016 okt. 15;221:944-50. https://doi.org/10.1016/j.ijcard.2016.07.111

Author

Madelaire, Christian ; Schou, Morten ; Nelveg-Kristensen, Karl Emil ; Schmiegelow, Michelle ; Torp-Pedersen, Christian ; Gustafsson, Finn ; Køber, Lars ; Gislason, Gunnar. / Use of digoxin and risk of death or readmission for heart failure and sinus rhythm : A nationwide propensity score matched study. I: International Journal of Cardiology. 2016 ; Bind 221. s. 944-50.

Bibtex

@article{80f6056791594dda85c9c85dfeb7cb1c,
title = "Use of digoxin and risk of death or readmission for heart failure and sinus rhythm: A nationwide propensity score matched study",
abstract = "BACKGROUND/OBJECTIVES: Digoxin is widely used as symptomatic treatment in heart failure (HF), but the role in contemporary treatment of HF with sinus rhythm (SR) is debatable. We investigated the risk of death and hospital readmission, according to digoxin use, in a nationwide cohort of digoxin-na{\"i}ve patients with HF and SR.METHODS: From Danish nationwide registries, digoxin-na{\"i}ve HF patients from 1996 to 2012 were identified. Patients with cardiac dysrhythmias or use of warfarin were excluded. Digoxin users and non-users were compared in propensity matched cox regression models with respect to primary outcomes of all-cause mortality and HF readmission.RESULTS: The study population comprised 5327 digoxin users and 10,654 matched non-users with a median age of 77. During follow-up 10,643 (66.6%) patients died and 7584 (47.5%) patients were readmitted due to HF. Use of digoxin was associated with increased risk of death (hazard ratio (HR): 1.19, 95%-CI: 1.15-1.24) and increased risk of HF readmission (HR: 1.19, 95%-CI: 1.13-1.25). Cumulative incidences of readmission, considering death as a competing risk was 50% for digoxin users and 47% for non-users. The associations applied regardless of concomitant HF treatment. In an exploratory analysis considering patients with previous digoxin use, no effect on mortality (HR: 1.00, 95%-CI: 0.94-1.06), nor on HF readmission (HR: 1.00, 95%-CI: 0.93-1.09) was observed.CONCLUSION: In chronic HF with SR, digoxin was associated with a slightly increased risk of death and was not associated with decreased HF readmission rates.",
keywords = "Journal Article",
author = "Christian Madelaire and Morten Schou and Nelveg-Kristensen, {Karl Emil} and Michelle Schmiegelow and Christian Torp-Pedersen and Finn Gustafsson and Lars K{\o}ber and Gunnar Gislason",
note = "Copyright {\textcopyright} 2016 Elsevier Ireland Ltd. All rights reserved.",
year = "2016",
month = oct,
day = "15",
doi = "10.1016/j.ijcard.2016.07.111",
language = "English",
volume = "221",
pages = "944--50",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

RIS

TY - JOUR

T1 - Use of digoxin and risk of death or readmission for heart failure and sinus rhythm

T2 - A nationwide propensity score matched study

AU - Madelaire, Christian

AU - Schou, Morten

AU - Nelveg-Kristensen, Karl Emil

AU - Schmiegelow, Michelle

AU - Torp-Pedersen, Christian

AU - Gustafsson, Finn

AU - Køber, Lars

AU - Gislason, Gunnar

N1 - Copyright © 2016 Elsevier Ireland Ltd. All rights reserved.

PY - 2016/10/15

Y1 - 2016/10/15

N2 - BACKGROUND/OBJECTIVES: Digoxin is widely used as symptomatic treatment in heart failure (HF), but the role in contemporary treatment of HF with sinus rhythm (SR) is debatable. We investigated the risk of death and hospital readmission, according to digoxin use, in a nationwide cohort of digoxin-naïve patients with HF and SR.METHODS: From Danish nationwide registries, digoxin-naïve HF patients from 1996 to 2012 were identified. Patients with cardiac dysrhythmias or use of warfarin were excluded. Digoxin users and non-users were compared in propensity matched cox regression models with respect to primary outcomes of all-cause mortality and HF readmission.RESULTS: The study population comprised 5327 digoxin users and 10,654 matched non-users with a median age of 77. During follow-up 10,643 (66.6%) patients died and 7584 (47.5%) patients were readmitted due to HF. Use of digoxin was associated with increased risk of death (hazard ratio (HR): 1.19, 95%-CI: 1.15-1.24) and increased risk of HF readmission (HR: 1.19, 95%-CI: 1.13-1.25). Cumulative incidences of readmission, considering death as a competing risk was 50% for digoxin users and 47% for non-users. The associations applied regardless of concomitant HF treatment. In an exploratory analysis considering patients with previous digoxin use, no effect on mortality (HR: 1.00, 95%-CI: 0.94-1.06), nor on HF readmission (HR: 1.00, 95%-CI: 0.93-1.09) was observed.CONCLUSION: In chronic HF with SR, digoxin was associated with a slightly increased risk of death and was not associated with decreased HF readmission rates.

AB - BACKGROUND/OBJECTIVES: Digoxin is widely used as symptomatic treatment in heart failure (HF), but the role in contemporary treatment of HF with sinus rhythm (SR) is debatable. We investigated the risk of death and hospital readmission, according to digoxin use, in a nationwide cohort of digoxin-naïve patients with HF and SR.METHODS: From Danish nationwide registries, digoxin-naïve HF patients from 1996 to 2012 were identified. Patients with cardiac dysrhythmias or use of warfarin were excluded. Digoxin users and non-users were compared in propensity matched cox regression models with respect to primary outcomes of all-cause mortality and HF readmission.RESULTS: The study population comprised 5327 digoxin users and 10,654 matched non-users with a median age of 77. During follow-up 10,643 (66.6%) patients died and 7584 (47.5%) patients were readmitted due to HF. Use of digoxin was associated with increased risk of death (hazard ratio (HR): 1.19, 95%-CI: 1.15-1.24) and increased risk of HF readmission (HR: 1.19, 95%-CI: 1.13-1.25). Cumulative incidences of readmission, considering death as a competing risk was 50% for digoxin users and 47% for non-users. The associations applied regardless of concomitant HF treatment. In an exploratory analysis considering patients with previous digoxin use, no effect on mortality (HR: 1.00, 95%-CI: 0.94-1.06), nor on HF readmission (HR: 1.00, 95%-CI: 0.93-1.09) was observed.CONCLUSION: In chronic HF with SR, digoxin was associated with a slightly increased risk of death and was not associated with decreased HF readmission rates.

KW - Journal Article

U2 - 10.1016/j.ijcard.2016.07.111

DO - 10.1016/j.ijcard.2016.07.111

M3 - Journal article

C2 - 27441473

VL - 221

SP - 944

EP - 950

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -

ID: 176867149